CVS Health grew its revenues by 2.6% in the second quarter, crediting this year-over-year improvement in part to its growing number of digital customers, its offering of biosimilar prescriptions and its closure of underperforming stores.“We extended our digital reach with nearly 60 million unique digital customers utilizing our platform to schedule health services appointments, fill prescriptions and purchase wellness products — all contributing to the growth in our business,” CVS Health President and CEO K ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of CVS Health Corporation (NYSE: CVS). Shareholders who purchased shares of CVS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/cvs-health-corporation-loss-submission-form-2/?id=94057&from=3 CLASS PERIOD: Ma ...

财务数据和关键指标变化 - 第二季度收入约911亿美元,同比增长2.6% [10][33] - 调整后营业利润超过37亿美元 [10] - 上半年经营活动产生的现金流约80亿美元,同比有所下降,主要由于Medicare付款时间和Medicare使用率的影响 [33] 各条业务线数据和关键指标变化 医疗保险业务 - 第二季度收入约325亿美元,同比增长超过21% [34] - 医疗会员人数近2700万,环比增加20万 [34] - 医疗保险利润率89.6%,同比上升340个基点,主要受Medicare Advantage利用率上升、2024年支付年度星级评级下降、Medicaid人群重症程度上升以及2023年个人交易所风险调整估计变更的影响 [35][38][39] - 预计2024年全年医疗保险利润率将在90.6%-90.8%之间,较之前指引上升80-100个基点 [51] - 2025年Medicare Advantage业务有望实现100-200个基点的利润率改善 [20][60] - 2025年商业业务预计将实现会员增长,保留率维持在高90%水平 [21] 药品与消费者健康业务 - 第二季度收入约298亿美元,同比增长3.7% [45] - 调整后营业利润约12亿美元,同比有所下降,主要受药品报销压力、前店销量下降以及与Medicare相关的某些付款时间的影响 [46] - 同店药房销售额同比增长超过9%,同店处方量增长6.5%,零售药房市场份额达到27.2%创新高 [47] - 同店前店销售额同比下降约4%,剔除OTC检测试剂盒影响后下降约2%,反映了消费需求的普遍疲软 [48] 健康服务业务 - 第二季度收入约422亿美元,同比下降约9%,主要受之前宣布失去一大客户以及持续的药品客户价格改善的影响 [42] - 调整后营业利润约19亿美元,同比增长超过1%,反映了采购经济性改善,部分被持续的药品客户价格改善和失去大客户所抵消 [43] - 第二季度处理的总处方量约4.71亿个,会员总数约9000万 [43] - Signify和Oak Street业务表现强劲,收入同比分别增长27%和32% [44] 公司战略和发展方向及行业竞争 - 公司正在推进创新的药品定价模式,包括CVS CostVantage和CVS Caremark TrueCost,以提高定价透明度和简单性 [14][15][104][105][123] - 生物类似药业务Cordavis为客户带来近4亿美元的净节省 [16] - 公司启动了多年期生产力提升计划,预计到2025年可实现超过5亿美元的利润增长 [17][81] - 公司正在加快整合医疗服务资产,如Signify和Oak Street,与Aetna、MinuteClinic和CVS Pharmacy等资产进行协同 [28][29] - 公司对FTC关于PBM行业的中期报告持有不同意见,认为PBM在降低药价方面发挥了关键作用 [26][117][118][119][120][121][124][125] 管理层对经营环境和未来前景的评论 - 医疗保险业务2024年表现未达预期,公司决定进行管理层变更,由CEO Karen Lynch和CFO Tom Cowhey直接接管该业务 [11][12] - 公司对2025年前景保持乐观,预计Medicare Advantage利润率将改善100-200个基点,个人交易所和Medicaid业务也有望改善 [20][39][60] - 公司将继续推进生产力提升计划,预计2025年可实现超过5亿美元的利润增长 [81] - 公司对自身在降低药价、提高定价透明度等方面的能力和成果充满信心,将继续推动行业变革 [26][118][119][123][124][125] 其他重要信息 - 公司服务超过1.86亿人,消费者同时使用2种及以上公司产品的人数增加近250万,体现了公司一体化模式的价值 [13] - 公司已有13.8万Aetna医疗会员使用Caremark,较去年增长13% [13] - 公司数字客户达6000万,可通过数字渠道预约健康服务、配药和购买保健产品 [13] - 公司已关闭851家门店,预计今年底完成900家门店的关闭目标,剩余门店基本都是盈利的 [23][24] 问答环节重要的提问和回答 问题1 **Lisa Gill 提问** 对于2025年Medicare Advantage业务,公司是否已在投标中充分考虑了2023年下半年和2024年上半年观察到的更高利用率趋势? [63][64] **Tom Cowhey 回答** 公司在2025年投标中采取了谨慎的假设,充分考虑了2023年下半年和2024年上半年观察到的更高利用率趋势。公司相信通过调整福利等措施,可实现100-200个基点的利润率改善。即使未来利用率持续高于预期,公司也有信心在2025年实现目标利润率。[65][66][67] 问题2 **Justin Lake 提问** 公司是否仍有信心实现2025年的双位数盈利增长目标,主要的推动因素和潜在阻碍因素有哪些? [74][75] **Tom Cowhey 回答** 公司仍有信心实现2025年的双位数盈利增长目标。主要推动因素包括:医疗保险业务利润率改善、商业业务会员增长、健康服务和药品与消费者健康业务的持续强劲表现,以及公司启动的生产力提升计划。潜在阻碍因素包括医疗保险业务的一些压力,但公司相信通过各项措施可以得到缓解。公司将在稍后时间提供更详细的2025年指引。[76][77][78][79][80][81] 问题3 **Charles Rhyee 提问** 公司如何加强与国会的沟通,让他们更好地理解PBM在降低药价方面的作用,以及

CVS Health (CVS) stock is in negative territory Wednesday after the pharmacy chain and healthcare benefits provider reported mixed results for its second quarter and slashed its full-year profit forecast.In the three months ended June 30, CVS said its revenue increased 2.6% year-over-year to $91.2 billion, driven by growth in its Health Care Benefits and Pharmacy & Consumer Wellness segments. However, its earnings per share (EPS) decreased 17.2% from the year-ago period to $1.83, primarily due to a decline ...

CVS Health on Wednesday cut its 2024 earnings outlook and announced its goal to cut $2 billion in costs through a multi-year productivity initiative as medical costs continue to rise. CVS reported that its adjusted earnings for the year will now be in the range of $6.40 to $6.65 per share, down from its earlier projection of at least $7 per share. This change reflects the "continued pressure in the Health Care Benefits segment," the company said.As part of its cost-cutting efforts, the retail pharmacy chain ...

CVS Health (CVS) reported $91.23 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 2.6%. EPS of $1.83 for the same period compares to $2.21 a year ago.The reported revenue represents a surprise of -0.35% over the Zacks Consensus Estimate of $91.56 billion. With the consensus EPS estimate being $1.74, the EPS surprise was +5.17%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...

KEY TAKEAWAYSCVS Health shares lost ground in early trading Wednesday after the pharmacy giant slashed its 2024 earnings guidance again amid increased medical costs.The company reported revenue for the second quarter that missed analysts' estimates, though earnings per share beat projections.CVS also announced the departure of the head of its Aetna unit. CVS Health (CVS) shares lost ground in early trading Wednesday after the pharmacy giant slashed its 2024 earnings guidance again amid increased medical cos ...

CVS Health Corporation (CVS) posted adjusted earnings per share (EPS) of $1.83 in the second quarter of 2024, down 17.2% year over year. However, the metric topped the Zacks Consensus Estimate by 5.2%. The adjusted EPS figure considers certain asset amortization costs, loss on assets held for sale and other adjustments.On a reported basis, the company’s GAAP earnings were $1.41, down 4.7% year over year.RevenuesRevenues in the second quarter rose 2.6% year over year to $91.23 billion. However, the top line ...

CVS Health (CVS) came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of $1.74 per share. This compares to earnings of $2.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.17%. A quarter ago, it was expected that this drugstore chain and pharmacy benefits manager would post earnings of $1.69 per share when it actually produced earnings of $1.31, delivering a surprise of -22.49%.Over the ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...